Two-drug combo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 80 with advanced colorectal cancer that has spread
- Your tumor must have a specific genetic marker called dMMR or MSI-H (your doctor can check this)
- You must be in generally good physical condition (ECOG score 0 to 2) and have at least one tumor that can be measured on a scan
- Your blood counts and organ function (liver, kidneys, clotting) must be within certain limits
- You cannot have had prior treatment with a PD-1/CTLA-4 dual immunotherapy
- You must not have active autoimmune disease, uncontrolled high blood pressure, or serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (tislelizumab, fruquintinib, and chidamide) for colorectal cancer that has spread to the liver and has not responded to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
Hear when a new Colo-rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.